Effect modification of the association between vancomycin trough concentration and acute kidney injury: A retrospective cohort study

Vancomycin exposure is associated with acute kidney injury (AKI), but the extent to which concomitant clinical factors modify this association remains uncertain. This study evaluated factors associated with vancomycin-related AKI and examined potential effect modification of the association between vancomycin trough concentration and AKI. This single-center retrospective cohort study used electronic health records of adults treated with vancomycin from January 2019 to June 2023. Factors associated with AKI were assessed using logistic regression, and interaction terms were used to evaluate whether the trough-AKI association differed according to selected comorbidities and concomitant medications. A systematic review and meta-analysis were also performed to place the cohort findings in the context of existing evidence. Among 1612 patients, 375 (23.2%) developed AKI. Higher vancomycin trough concentration, concomitant loop diuretic use, and concomitant piperacillin/tazobactam (PIP/TAZ) use were independently associated with AKI. Statistically significant interactions with trough concentration were observed for PIP/TAZ, chronic kidney disease, hypertension, and angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use (interaction P = .036, .023, .003, and .006, respectively). Compared with patients not receiving PIP/TAZ and with trough levels < 17 mg/L, the odds of AKI were higher among patients receiving PIP/TAZ with trough levels < 17 mg/L (odds ratio [OR]: 1.62, 95% CI: 1.42-1.85) and were highest among those receiving PIP/TAZ with trough levels ≥17 mg/L (OR: 2.03, 95% CI: 1.36-2.98). Among patients not receiving PIP/TAZ, trough levels ≥17 mg/L were associated with higher AKI odds (OR: 1.43, 95% CI: 1.26-1.63). Concomitant PIP/TAZ identified a population with increased AKI risk across trough strata, whereas the incremental association of a higher trough level was less apparent among PIP/TAZ users. These observational findings support individualized assessment of vancomycin exposure together with concurrent AKI risk factors and should not be interpreted as establishing a new therapeutic trough target.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-20
DOI
https://doi.org/10.1097/md.0000000000051407
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect modification of the association between vancomycin trough concentration and acute kidney injury: A retrospective cohort study

Chun-Hao Yin, Yi‐Chia Su, Ying‐Chun Li, Ching-Shiang Yang et al.
2 links
Medicine
Acute Kidney Injury Research
article

Effect modification of the association between vancomycin trough concentration and acute kidney injury: A retrospective cohort study

Chun-Hao Yin, Yi‐Chia Su, Ying‐Chun Li, Ching-Shiang Yang, Yao-Shen Chen, Cheng-Len Sy, Jin-Shuen Chen, Kuan-Sheng Wu, Yu-Ling Tseng
article en

Abstract

Vancomycin exposure is associated with acute kidney injury (AKI), but the extent to which concomitant clinical factors modify this association remains uncertain. This study evaluated factors associated with vancomycin-related AKI and examined potential effect modification of the association between vancomycin trough concentration and AKI. This single-center retrospective cohort study used electronic health records of adults treated with vancomycin from January 2019 to June 2023. Factors associated with AKI were assessed using logistic regression, and interaction terms were used to evaluate whether the trough-AKI association differed according to selected comorbidities and concomitant medications. A systematic review and meta-analysis were also performed to place the cohort findings in the context of existing evidence. Among 1612 patients, 375 (23.2%) developed AKI. Higher vancomycin trough concentration, concomitant loop diuretic use, and concomitant piperacillin/tazobactam (PIP/TAZ) use were independently associated with AKI. Statistically significant interactions with trough concentration were observed for PIP/TAZ, chronic kidney disease, hypertension, and angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use (interaction P = .036, .023, .003, and .006, respectively). Compared with patients not receiving PIP/TAZ and with trough levels < 17 mg/L, the odds of AKI were higher among patients receiving PIP/TAZ with trough levels < 17 mg/L (odds ratio [OR]: 1.62, 95% CI: 1.42-1.85) and were highest among those receiving PIP/TAZ with trough levels ≥17 mg/L (OR: 2.03, 95% CI: 1.36-2.98). Among patients not receiving PIP/TAZ, trough levels ≥17 mg/L were associated with higher AKI odds (OR: 1.43, 95% CI: 1.26-1.63). Concomitant PIP/TAZ identified a population with increased AKI risk across trough strata, whereas the incremental association of a higher trough level was less apparent among PIP/TAZ users. These observational findings support individualized assessment of vancomycin exposure together with concurrent AKI risk factors and should not be interpreted as establishing a new therapeutic trough target.

MedicineVol. 105(47)
National Tainan Institute of Nursing (TW), National Sun Yat-sen University (TW), National Yang Ming Chiao Tung University (TW), Kaohsiung Medical University (TW), Tajen University (TW), Kaohsiung Veterans General Hospital (TW), Chia Nan University of Pharmacy and Science (TW), National Cheng Kung University (TW)
Good health and well-being
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon